BOSTON, MA — August 5, 2026 — Leads & Copy — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders, announced that its management team will participate in the Canaccord Genuity 46th Annual Growth Conference. The conference is scheduled to take place in Boston, MA, on Tuesday, August 11, 2026.
Company leadership is slated to deliver a fireside chat and engage in one-on-one investor meetings. During the fireside chat, management will provide updates on the ongoing clinical development program for neflamapimod, the Company’s lead drug candidate. The fireside chat is scheduled for 11:30 AM to 11:55 AM ET on August 11, 2026.
A webcast of the fireside chat will be available on the investor section of the CervoMed website. The Company’s lead drug candidate, neflamapimod, is an oral small molecule designed to inhibit a key enzyme involved in neuroinflammation and neurodegeneration, targeting critical disease processes in degenerative brain disorders.
CervoMed recently concluded its Phase 2b RewinD-LB trial, which evaluated neflamapimod in patients diagnosed with dementia with Lewy bodies (DLB), specifically those without Alzheimer’s disease co-pathology. In November 2025, the Company reported agreement with the U.S. Food and Drug Administration (FDA) on a potential registration pathway for neflamapimod in DLB. The initiation of a Phase 3 trial in DLB is contingent upon securing a partnership and/or additional financing.
Furthermore, CervoMed has completed enrollment in its Phase 2a clinical trial assessing neflamapimod for nfvPPA, a subtype of frontotemporal disorders. Interim biomarker data from this trial is expected in the early fourth quarter of 2026. The Company anticipates dosing the first patient in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Source: CervoMed Inc.
